Top Story
Medicare's Provenge review comes into clearer focus
With billions in revenue at stake, every new twist and turn in the saga revolving around the rollout of Provenge gets put under the microscope. Any possibility of market restrictions, a fear raised by CMS's decision earlier in the summer to review Provenge's use in the elderly, is enough to panic investors. To some, it looked as if the agency was considering that it might not pay for Provenge at all. ReportRecent News
NIAID awards $46.3 million in vax grants and contracts
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded two grants to vaccine makers for anthrax and hepatitis B vaccines, respectively. Emergent BioSolutions received a contract worth up to $28.7 million for its third generation anthrax vaccine. Dynavax Technologies, based in Berkeley, CA, received a portion of a five-year, $17.6 million grant. ReportFrom The Network
Also Noted
Vaccine Market
With an eye toward eliminating measles as a threat, China is preparing to vaccinate 100 million children later this month. Health officials in the country say it will be the fourth infection to be targeted by a nationwide campaign. Story
With its smoking cessation drug NicVAX in two late-stage trials, Nabi Pharmaceuticals says that it has lined up Dyosynth RTP to manufacture a key ingredient for commercial supplies of the vaccine. Report
Xcellerex is providing bioreactors to Project GreenVax, a new initiative to develop vaccines from tobacco plants. Report
Read more >>Press Releases
- 'Charitable' Behavior Found in Bacteria
- Sinobiomed Announces New Chief Executive Officer
- Actavis Receives FDA Approval of Atomoxetine HCl Capsules
- Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
- Cardiome Achieves $30 Million Milestone
- Generex Oncology Announces Consultancy of Dr. George E. Peoples, MD
